Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Late-Stage Pipeline

50%

2 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 4
2(50.0%)
Phase 1
1(25.0%)
N/A
1(25.0%)
4Total
Phase 4(2)
Phase 1(1)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT06235450Phase 1Unknown

A Usability Study of iTEAR100 For Combined EyeLid Microblepharoexfoliation and Neurostimulation

Role: lead

NCT05304637Phase 4Unknown

Usability, Immediate, and 30 Day Effect of External Neuromodulation With iTEAR100 Generation 2 in Dry Eye Patients

Role: lead

NCT05304650Phase 4Unknown

A Usability Study of External Neuromodulation With iTEAR100 Generation 2

Role: lead

NCT04763018Not ApplicableUnknown

Study of External Neuromodulation to Improve Signs and Symptoms of Dry Eye in Visual Display Terminal Users

Role: lead

All 4 trials loaded